ReviewEuropean journal of medical research2011
Epidemiology and antifungal resistance in invasive candidiasis.
Review in European journal of medical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global prevalence and trends of fluconazole resistance in non-albicans Candida species: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Pooled it
- Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis.PloS one · 2012Pooled it
- Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.BMC infectious diseases · 2014Trial
- Global surveillance ofAntimicrobial agents and chemotherapy · 2026Article
- Candidemia in Pediatric-Clinic: Frequency of Occurrence,Diagnostics (Basel, Switzerland) · 2024Article
- Evaluation of the effect of Jaftex herbal mouthwash on the growth ofJournal of family medicine and primary care · 2021Article
- Investigation of culturable human gut mycobiota from the segamat community in Johor, Malaysia.World journal of microbiology & biotechnology · 2021Article
- Non-Current medical mycology · 2021Article
- Species Diversity and Antifungal Susceptibilities of Oral Yeasts from Patients with Head and Neck Cancer.Infection and drug resistance · 2021Article
- Ozonized Gel Against FourMaterials (Basel, Switzerland) · 2020Article
- Streptomyces sp. BV410 isolate from chamomile rhizosphere soil efficiently produces staurosporine with antifungal and antiangiogenic properties.MicrobiologyOpen · 2020Article
- Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.Frontiers in cellular and infection microbiology · 2020Review
- Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China.BMC infectious diseases · 2019Article
- Resisting resistance: gearing up for war.MedChemComm · 2019Review
- Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study.Infectious diseases and therapy · 2019Article
- Investigating Antifungal Susceptibility inFrontiers in cellular and infection microbiology · 2019Review
- Antifungal effect of tissue conditioners containing poly(acryloyloxyethyltrimethyl ammonium chloride)-grafted chitosan onJournal of dental sciences · 2018Article
- Article
- A chromosome 4 trisomy contributes to increased fluconazole resistance in a clinical isolate of Candida albicans.Microbiology (Reading, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology of Candida infections has changed over the last two decades: The number of patients suffering from such infections has increased dramatically and the Candida species involved have become more numerous as Candida albicans is replaced as an infecting agent by various non-C. albicans species (NAC). At the same time, additional antifungal agents have become available. The different Candida species may vary in their susceptibility for these various antifungals. This draws more attention to in vitro susceptibility testing. Unfortunately, several different test methods exist that may deliver different results. Moreover, clinical breakpoints (CBP) that classify test results into susceptible, intermediate and resistant are controversial between CLSI and EUCAST. Therefore, clinicians should be aware that interpretations may vary with the test system being followed by the microbiological laboratory. Thus, knowledge of actual MIC values and pharmacokinetic properties of individual antifungal agents is important in delivering appropriate therapy to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.